Literature DB >> 21928278

Epidemiological investigation of the UGT2B17 polymorphism in doping control urine samples and its correlation to T/E ratios.

Patricia Anielski1, Juliane Simmchen, Lars Wassill, Dirk Ganghofner, Detlef Thieme.   

Abstract

The deletion polymorphism of the enzyme UGT2B17 is known to correlate with the level of the testosterone to epitestosterone (T/E) ratio in urine specimen. Due to the importance of the T/E ratio to detect testosterone abuse in doping analysis, a PCR-ELISA system (Genotype® UGT test, AmplexDiagnostics) was established to identify the UGT2B17 phenotype in urine samples. Epidemiological investigations in a set of 674 routine doping controls (in- and out-of-competition) resulted in 22.8% homozygote gene-deleted and 74.5% UGT2B17-positive athletes. The validated test system has shown to be robust and sensitive: in only 18 cases (2.7%) isolation of cell material from urine failed. Following hydrolysis of glucuronidated conjugates, steroids were analyzed as bis-TMS derivatives by gas chromatography-mass spectrometry (GC-MS), for example, testosterone (T) and epitestosterone (E). Additionally, isotope ration mass spectrometry (IRMS) analysis and luteinizing hormone (LH) measurement were applied. Mean T/E ratios significantly correlated with the UGT2B17 phenotype (del: T/E 0.9; pos: 1.7), however the values did not differ as distinctive as reported in previous studies. Additionally, the T/E ratios in the gene-deleted group did not show a normal curve of distribution (median of T/E 0.5). Obviously, beside the UGT2B17 deletion further influences have to be taken into account, for example, polymorphisms or induction of other metabolizing enzymes. Our results indicate that the UGT2B17 polymorphism might be insufficient when utilized solely as a crucial parameter for individual interpretation of T/E in urine. Nevertheless, the detection of the UGT2B17-gene deletion in urine samples would provide additional information important for gathering evidence in analysis of steroids in doping control.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21928278     DOI: 10.1002/dta.332

Source DB:  PubMed          Journal:  Drug Test Anal        ISSN: 1942-7603            Impact factor:   3.345


  6 in total

Review 1.  Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement.

Authors:  Harrison G Pope; Ruth I Wood; Alan Rogol; Fred Nyberg; Larry Bowers; Shalender Bhasin
Journal:  Endocr Rev       Date:  2013-12-17       Impact factor: 19.871

2.  Genetic and phenotypic variation in UGT2B17, a testosterone-metabolizing enzyme, is associated with BMI in males.

Authors:  Andy Z X Zhu; Lisa S Cox; Jasjit S Ahluwalia; Caroline C Renner; Dorothy K Hatsukami; Neal L Benowitz; Rachel F Tyndale
Journal:  Pharmacogenet Genomics       Date:  2015-05       Impact factor: 2.089

3.  Antidoping programme and biological monitoring before and during the 2014 FIFA World Cup Brazil.

Authors:  Norbert Baume; Nicolas Jan; Caroline Emery; Béatrice Mandanis; Carine Schweizer; Sylvain Giraud; Nicolas Leuenberger; François Marclay; Raul Nicoli; Laurent Perrenoud; Neil Robinson; Jiri Dvorak; Martial Saugy
Journal:  Br J Sports Med       Date:  2015-05       Impact factor: 13.800

Review 4.  Confounding factors and genetic polymorphism in the evaluation of individual steroid profiling.

Authors:  Tiia Kuuranne; Martial Saugy; Norbert Baume
Journal:  Br J Sports Med       Date:  2014-05       Impact factor: 13.800

5.  Urinary Steroid Profile in Elite Female Athletes in Relation to Serum Androgens and in Comparison With Untrained Controls.

Authors:  Emma Eklund; Alexander Andersson; Lena Ekström; Angelica Lindén Hirschberg
Journal:  Front Physiol       Date:  2021-08-30       Impact factor: 4.566

Review 6.  Genes in sport and doping.

Authors:  A Pokrywka; P Kaliszewski; E Majorczyk; A Zembroń-Łacny
Journal:  Biol Sport       Date:  2013-07-22       Impact factor: 2.806

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.